The U.S. Food and Drug Administration has given the injectable Xolair (omalizumab) the green light for use in decreasing the risk of life-threatening reactions to certain foods. Doctors weighed in.
Join Fox News for access to this content Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the
(CTN News) - The US Food and Drug Administration authorised Xolair, a medicine that reduces the intensity of allergy reactions in those who are allergic to
Xolair, which is developed and co-promoted by Genentech and Novartis in the US, was originally approved in 2003 for the treatment of moderate to severe persistent allergic asthma in certain patients.